Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from JJ.

J&J wins pause of baby powder trials, must face new suits

Johnson & Johnson must face new lawsuits accusing the company of selling tainted baby powder that caused cancer, a judge ruled, opening the company up to court actions that had been halted for 19 months.

Tribune News Service

Legend Breaks Out After Leaked Documents Show Promise In $9.6 Billion Market

Legend Biotech is staring down a $9.6 billion opportunity, an analyst said Wednesday as LEGN stock soared on positive cancer test results.

Investors Business Daily

The Surprising Source Of Johnson & Johnson's First-Quarter Beat And Raise

Johnson & Johnson beat first-quarter expectations Tuesday and raised its full-year outlook. But JNJ stock ended the trading day lower.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

J&J’s first attempt to escape cancer claims with bankruptcy failed. Now it’s trying again

Johnson & Johnson’s first attempt at using bankruptcy to escape claims that its popular baby powder caused cancer was an expensive gamble that drew public scorn and ended in failure.

Tribune News Service

Johnson & Johnson Pops After Sweetening Its Talc Settlement By Nearly $7 Billion

J&J reached an $8.9 billion settlement in ongoing litigation over its talc-based baby powders, leading JNJ stock to rise Wednesday.

Investors Business Daily

First Thing: Trump attacks hush money case in grievance-filled Mar-a-Lago speech

Former president appeared subdued in New York, only to return to his inflammatory ways in Florida. Plus, the campaigners using using dating apps to boost voter turnout

The Guardian - UK

Johnson & Johnson proposes paying $8.9 billion to settle talcum powder lawsuits

Under a proposal, a J&J subsidiary will re-file for bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

WEKU

Read news from The Economist, FT, and more,
with one subscription

Johnson & Johnson proposes $8.9bn settlement fund for talcum powder cancer lawsuits

The offer will have to be approved by a bankruptcy judge

The Independent UK

Johnson & Johnson proposes $8.9 billion payout to settle talcum powder lawsuits

A subsidiary of the company will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history.

Chicago Sun-Times

J&J proposes paying $8.9B to settle talcum powder lawsuits

Johnson & Johnson is earmarking nearly $9 billion to cover allegations that its baby power containing talc caused cancer

The Independent UK

Buy Johnson & Johnson Stock and Its 3% Dividend Yield?

Johnson & Johnson stock in Q1 declined for nine straight weeks. Is that the selloff that long investors had been waiting for?

The Street

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out

Johnson & Johnson ducked out of the RSV vaccine race Wednesday, leaving Pfizer, GSK and Moderna to duke it out.

Investors Business Daily

Buy the Dip in Johnson & Johnson and Its Near-3% Dividend Yield

Johnson & Johnson stock has fallen in seven straight weeks, trades at less than 15 times earnings and pays a near-3% dividend yield. Plus, support is nearby.

The Street

J&J Stock Jolted by NYSE Glitch, and Earnings Don’t Help. Check the Chart.

Johnson & Johnson stock has fallen in 10 straight sessions and was jolted by NYSE issues and the earnings report. Here's the trade.

The Street

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

How J&J's Mostly Defunct Covid Shot Still Managed To Hamper Sales; Danaher Dives

Covid vaccines took a major toll on Johnson & Johnson and Danaher early Tuesday, hitting J&J's fourth-quarter sales and Danaher's guidance.

Tribune News Service

Employers use patient assistance programs to offset their own costs

Anna Sutton was shocked when she received a letter from her husband’s job-based health plan stating that Humira, an expensive drug used to treat her daughter’s juvenile arthritis, was now on a long list of medications considered “nonessential benefits.”

The Street

Johnson & Johnson Stock Can Fly if It Clears This Level

One resistance level is holding back a more notable rally in Johnson & Johnson stock.

Investors Business Daily

Johnson & Johnson Notches Quarterly Beat, Outplaying Exchange-Rate Headwinds

Johnson & Johnson topped third-quarter expectations on Thursday despite exchange-rate challenges, but JNJ stock pared back gains.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

BeiGene Takes On Johnson & Johnson's Blockbuster Cancer Drug — And Wins

BeiGene stock catapulted Wednesday after the company's leukemia treatment beat out a blockbuster drug from Johnson & Johnson.

Chicago Tribune

Movement in the Tylenol murders: Law enforcement seeks to persuade prosecutors to act on ‘chargeable’ case

CHICAGO — As the 40th anniversary of the 1982 Tylenol murders approaches, investigators are working with prosecutors on a now-or-maybe-never effort to hold a longtime suspect responsible for the poisonings that killed seven people in the Chicago area, the Tribune has learned.

WEKU

J&J tried to block lawsuits from 40,000 cancer patients. A court wants answers

Critics say a legal maneuver by one of the world's wealthiest corporations could set a precedent, allowing non-bankrupt companies and rich individuals to avoid liability for wrongdoing.

The Street

Johnson & Johnson Stock Has Major Support on the Chart

Johnson & Johnson affirmed its full-year outlook and announced a new $5 billion buyback. Should you be a buyer right now?

Investors Business Daily

Bristol Myers Squibb, Bayer Stocks Hit The Deck On Blood Thinner Flops

Blood thinners produced by drug giants Bristol Myers and Bayer fell short of predictions, leading shares of both stocks down Monday.

The Hindu

J&J continues to sell talc-based baby powder in India, despite discontinuing in U.S. and Canada

Company says India is part of global transition to cornstarch-based powder

The Guardian - UK

Winslow Homer, Cézanne and Zaha Hadid: the best art and architecture of autumn 2022

The exhibition of the year is here, plus we have South Korean pop culture, a Sudanese women’s champion, decoded Egyptian hieroglyphs, Zaha Hadid’s ‘yonic stadium’ and a rare showing for the ‘American Turner’

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.